Current Data from the first Head-to-Head Study on Biologic Therapy in Ulcerative Colitis Patients Clinical Remission and Mucosal Healing in Adults: Vedolizumab superior to Adalimumab

被引：0
|
作者：
Thaesler, Elke
机构：
来源：
VISCERAL MEDICINE | 2019年 / 35卷 / 04期
关键词：
MAINTENANCE THERAPY; INDUCTION; DISEASE;
D O I：
10.1159/000502370
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：275 / 275
页数：1
相关论文
共 50 条
  • [1] VARSITY: First Head-to-Head-Study in CED - Vedolizumab (Entyvio®) is superior to Adalimumab achieving clinical Remission and Mucosa Healing in adult Patients with ulcerative Colitis
    不详
    VISCERAL MEDICINE, 2019, 35 (03) : 198 - 198
  • [2] VEDOLIZUMAB SHOWS SUPERIOR EFFICACY VERSUS ADALIMUMAB: RESULTS OF VARSITY-THE FIRST HEAD-TO-HEAD STUDY OF BIOLOGIC THERAPY FOR MODERATE-TO-SEVERE ULCERATIVE COLITIS
    Sands, Bruce E.
    Peyrin-Biroulet, Laurent
    Loftus, Edward V.
    Danese, Silvio
    Colombel, Jean Frederic
    Abhyankar, Brihad
    Chen, Jingjing
    Rogers, Raquel
    Lirio, Richard A.
    Bornstein, Jeffrey D.
    Schreiber, Stefan
    GASTROENTEROLOGY, 2019, 156 (06) : S81 - S81
  • [3] VARSITY: Vedolizumab showed superior Efficacy than that of Adalimumab in terms of clinical Remission and Mucosal Healing in Patients with moderate to severe active Ulcerative colitis
    不详
    VISCERAL MEDICINE, 2019, 35 (05) : 330 - 330
  • [4] Vedolizumab and Adalimumab in Biologic-Naive Ulcerative Colitis: Comparison of Patient-Level Clinical Trial Data and VARSITY for Week 6 Clinical Remission
    Narula, Neeraj
    Wong, Emily C. L.
    Dulai, Parambir S.
    Marshall, John K.
    Jairath, Vipul
    Reinisch, Walter
    DIGESTIVE DISEASES AND SCIENCES, 2023, 68 (06) : 2658 - 2666
  • [5] Vedolizumab and Adalimumab in Biologic-Naïve Ulcerative Colitis: Comparison of Patient-Level Clinical Trial Data and VARSITY for Week 6 Clinical Remission
    Neeraj Narula
    Emily C. L. Wong
    Parambir S. Dulai
    John K. Marshall
    Vipul Jairath
    Walter Reinisch
    Digestive Diseases and Sciences, 2023, 68 : 2658 - 2666
  • [6] Histologic Remission (NANCY Index) is Superior to Endoscopic Mucosal Healing in Predicting Relapse Free Survival in Patients With Ulcerative Colitis in Clinical and Endoscopic Remission
    Wang, Hunter
    Fewings, Ingrid
    Bornman, Lee
    Shadbolt, Bruce
    Fadia, Mitali
    Subramaniam, Kavitha
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2023, 57 (05) : 494 - 500
  • [7] Head-to-head comparison of 5 fecal markers to predict response to induction and maintenance therapy with infliximab in ulcerative colitis patients; a prospective study
    Frin, A. C.
    Nancey, S.
    Filippi, J.
    Boschetti, G.
    Flourie, B.
    Drai, J.
    Ferrari, P.
    Hebuterne, X.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S263 - S264
  • [8] Histological remission (NANCY index) is superior to endoscopic mucosal healing in predicting relapse-free survival in patients with ulcerative colitis in clinical and endoscopic remission
    Wang, H.
    Fewings, I.
    Bornman, L.
    Shadbolt, B.
    Fadia, M.
    Subramaniam, K.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S71 - S71
  • [9] Clinical effectiveness and safety of first-line biologic vedolizumab as a monotherapy or combination therapy in ulcerative colitis and Crohn's disease patients: results from the EVOLVE study
    Bressler, B.
    Yarur, A.
    Kopylov, U.
    Bassel, M.
    Brett, N.
    Colby, C.
    Lopez, C.
    Saha, S.
    Kifnidi, C.
    Agboton, C.
    Adsul, S.
    Demuth, D.
    Luo, M.
    Wang, S.
    Mantzaris, G. J.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S381 - S382
  • [10] CLINICAL EFFECTIVENESS AND SAFETY OF FIRST-LINE BIOLOGIC VEDOLIZUMAB AS A MONOTHERAPY OR COMBINATION THERAPY IN ULCERATIVE COLITIS AND CROHN'S DISEASE PATIENTS: RESULTS FROM THE EVOLVE STUDY
    Bressler, Brian
    Yarur, Andres J.
    Kopylov, Uri
    Bassel, Marielle
    Brett, Neil R.
    Colby, Chris
    Lopez, Claudia
    Saha, Sumit
    Kifnidi, Christina
    Agboton, Christian
    Adsul, Shashi
    Demuth, Dirk
    Luo, Michelle
    Wang, Song
    Mantzaris, Gerassimos J.
    GASTROENTEROLOGY, 2020, 158 (06) : S407 - S407
12345